Lawsuit accuses Apple of stealing trade secrets to create Apple Pay
In a complaint made public on Thursday, Fintiv said Apple Pay's key features were based on technology developed by CorFire, which Fintiv bought in 2014, and now used in hundreds of millions of iPhones, iPads, Apple Watches and MacBooks.
Apple did not immediately respond to requests for comment.
Fintiv, based in Austin, Texas, said Apple held multiple meetings in 2011 and 2012 and entered nondisclosure agreements with CorFire aimed at licensing its mobile wallet technology, to capitalize on fast-growing demand for contactless payments.
Instead, and with the help of CorFire employees it lured away, Apple used the technology and trade secrets to launch Apple Pay in the United States and dozens of other countries, beginning in 2014, the complaint said.
Fintiv also said Apple has led an informal racketeering enterprise by using Apple Pay to generate fees for credit card issuers such as Bank of America, Capital One, Citigroup, JPMorgan Chase and Wells Fargo, and the payment networks American Express, Mastercard and Visa.
"This is a case of corporate theft and racketeering of monumental proportions," enabling Cupertino, California-based Apple to generate billions of dollars of revenue without paying Fintiv "a single penny," the complaint said.
In a statement, Fintiv's lawyer Marc Kasowitz called Apple's conduct "one of the most egregious examples of corporate malfeasance" he has seen in 45 years of law practice.
The lawsuit in Atlanta federal court seeks compensatory and punitive damages for violations of federal and Georgia trade secrets and anti-racketeering laws, including RICO.
Apple is the only defendant. CorFire was based in Alpharetta, Georgia, an Atlanta suburb.
On August 4, a federal judge in Austin dismissed Fintiv's related patent infringement lawsuit against Apple, four days after rejecting some of Fintiv's claims, court records show.
Fintiv agreed to the dismissal, and plans to "appeal on the existing record," the records show.
The case is Fintiv Inc v Apple Inc, U.S. District Court, Northern District of Georgia, No. 25-04413.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
3 minutes ago
- Telegraph
Three more victims of 9/11 identified by DNA
Three more victims of the 9/11 attacks have been identified using DNA analysis. Officials in New York City named the individuals as Ryan Fitzgerald of Floral Park, New York, and Barbara Keating of Palm Springs, California. Another individual, an adult woman, was identified also but her details were withheld at the request of her family. News that the 1,651st, 1,652nd and 1,653rd victims have been positively identified 24 years after the Al-Qaeda attacks on New York and Washington DC, highlighted the fact that a little more than half of the 2,753 people killed that day have not been. 'The pain of losing a loved one in the September 11th terror attacks echoes across the decades, but with these three new identifications, we take a step forward in comforting the family members still aching from that day,' said Mayor Eric Adams. He added: 'As a former law enforcement officer who served our city on 9/11, I understand deeply the feeling of loss so many families have experienced. We hope the families receiving answers from the Office of Chief Medical Examiner can take solace in the city's tireless dedication to this mission.' New York media said Fitzgerald, 26, was working as a currency trader at Fiduciary Trust International in the south tower of the World Trade Centre. Fitzgerald's mother, Diane Parks, said he had recently moved to New York City. When she saw his credit card bill after his death, she realised he had been enjoying his new-found independence, buying clothes at Banana Republic and presents for his girlfriend. In an article by the New York Times, Ms Parks said he had told her of his intention to attend a friend's bachelor party in Las Vegas. She said that at the time, she advised him against it, but she was glad he went. ''It made me feel good that he enjoyed the summer because it was the last summer of his life,' she said. Keating, who was aged 72 and a grandmother, was onboard the American Airlines Flight 11 that left Boston and was due to head to Los Angeles when the jet was seized by the hijackers. After her death, Paul Keating, one of her five sons, said in an obituary she was 'smart, tough, professional and funny'. Keating spent more than 25 years in public service, much of it with the non-profit Big Brothers Big Sisters of South Middlesex, outside of Boston. Her family said she had been widowed 20 years before she lost her life and had divided her time between Cape Cod, Mass and California. In Palm Springs, she drove a red convertible and attended church every day. 'Nearly 25 years after the disaster at the World Trade Center, our commitment to identify the missing and return them to their loved ones stands as strong as ever,' Chief Medical Examiner Ryan Graham said. 'Each new identification testifies to the promise of science and sustained outreach to families despite the passage of time. We continue this work as our way of honouring the lost.' Sharon Premoli, a 9/11 survivor who was on the 80th floor of the north tower, told The Telegraph that identifying victims was important because it gives families closure. 'While I did not lose a family member on 9/11, I know from having spoken to some who have yet to get a definitive identification, that to them, their loved one has disappeared,' Ms Premoli said. 'That disappearance has to exacerbate a grief that may never subside. Losing a child, a spouse or partner, or a sibling with no remains prevents any kind of closure.'
Reuters
3 minutes ago
- Reuters
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech
Aug 7 (Reuters) - German drugmaker CureVac ( opens new tab and GSK (GSK.L), opens new tab reached an agreement with BioNTech ( opens new tab and Pfizer (PFE.N), opens new tab on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S. The settlement comes after BioNTech agreed to acquire its domestic peer CureVac in a $1.25 billion all-stock deal in June. Three years ago, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the company and two of its subsidiaries for infringement of its intellectual property rights. CureVac had said that its claim to intellectual property rights was based on more than two decades of work on mRNA technology, some of which was used by BioNTech and Pfizer for the development and sale of their Comirnaty coronavirus vaccine. CureVac's efforts to develop an mRNA-based COVID-19 vaccine did not come to fruition during the pandemic, whereas BioNTech and its partner Pfizer chalked up more than $40 billion in combined vaccine sales in 2021 and 2022.
Daily Mail
3 minutes ago
- Daily Mail
'The General' who ran '$4million surrogacy house of horrors' breaks cover... after sickening footage of babies being degraded
He was 'the general' who barked orders at staff and she was the 'mastermind' and manipulator with an explosive temper. These are the claims from former staff of Guojun Xuan and his girlfriend, Silvia Zhang, the couple accused of running a disturbing surrogacy business scheme in California.
